Similar articles

• Mineral and bone disorders in patients on dialysis: physiology and clinical consequences.

  McCarley PB, Arjomand M. McCarley PB, et al. Nephrol Nurs J. 2008 Jan-Feb;35(1):59-64. Nephrol Nurs J. 2008. PMID: 18372764 Review.
• [Bone disease in patients with chronic renal failure and during long-term hemodialysis].

  Flury W. Flury W. Ther Umsch. 1972 Sep;29(9):554-9. Ther Umsch. 1972. PMID: 4628712 German. No abstract available.
• [The course of osteodystrophy in patients with chronic kidney failure on hemodialysis].

  Zemchenko AIu, Shostka GD. Zemchenko AIu, et al. Urol Nefrol (Mosk). 1993 Nov-Dec;(6):51-4. Urol Nefrol (Mosk). 1993. PMID: 8160326 Review. Russian. No abstract available.
• [Prevention and treatment of renal osteodystrophy: present and future].

  Fernández E, Craver L. Fernández E, et al. Nefrologia. 2006;26 Suppl 3:19-27. Nefrologia. 2006. PMID: 17469423 Review. Spanish. No abstract available.
• Suppression of secondary hyperparathyroidism by propranolol in renal failure patients.

  Besarab A, Caro JF, Ihle BU, Burke JF Jr, Glennon JA, Fischer JA. Besarab A, et al. Nephron. 1981;27(3):127-33. doi: 10.1159/000182038. Nephron. 1981. PMID: 7219643